VRTX241206C490000
- 1.80
- -1.24-40.79%
Vertex Pharmaceuticals Newsroom
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
10 Health Care Stocks Whale Activity In Today's Session
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Express News | CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026
Express News | CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Looking Into Vertex Pharmaceuticals's Recent Short Interest